West Pharmaceutical Services ahead of earnings: what the market expects
West Pharmaceutical Services reports quarterly results on Thursday morning. Analysts expect revenue growth of 2.8% year on year, down from 7.7% a year earlier.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
West Pharmaceutical Services, a healthcare products maker, will publish its quarterly results on Thursday morning, according to stockstory.org. Last quarter the company reported revenue of $872.3 million, up 13.8% year on year, and beat analysts' expectations for both revenue and earnings per share.
For the current quarter, the market expects revenue to rise about 2.8% year on year, slower than the 7.7% gain posted a year earlier. Analysts have broadly kept their estimates unchanged over the past 30 days. Among peers in the drug development inputs and services segment, Repligen reported revenue growth of 10.9%, beating forecasts by 1.1%, while Medpace posted 8.5% growth in line with consensus; Medpace shares fell 1.3% after its report.
West Pharmaceutical shares have gained 5.8% over the past month, and the average analyst price target stands at $416.40 against a current share price of $397.50.
why it matters
The report matters for investors in the drug development services sector, where shares have risen 3.6% on average over the past month. Because expected revenue growth is slowing sharply from last year, the company's quarterly figures and its guidance commentary will be closely watched.
tags
instruments
sources
- West Pharmaceutical Services earnings: what to look for from WST — stockstory.org, 28 October 2026 at 03:10 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗